| 股票代码：600272 | 股票简称：开开实业 编号：2023—030 | | --- | --- | | 900943 | 开开 B 股 | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要风险提示： ●上海开开实业股份有限公司（以下简称"公司"）已于 2023 年 8 月 12 日披露《股票交易异常波动公告》（公告编号：2023-029）。 2023 年 8 月 14 日，公司 A 股股票再次涨停。A 股股票于 2023 年 8 月 9 日至今，连续 4 个交易日内出现 3 个涨停，收盘价格涨幅偏离值累 计超过 30%，换手率超过 80%。 鉴于公司 A 股股价短期涨幅较大，换手率较高，可能存在非理性 炒作风险，敬请广大投资者注意二级市场交易风险，理性决策，注意 投资风险。现对有关事项和风险说明情况如下： 一、二级市场交易的风险 公司A股股票于2023年8月9日、2023年8月10日、2023年8月11 日、2023年8月14日连续4个交易日内出现3个涨停，股价累计上涨超 过30%，换手率累计达80%。近期公司股票 ...

| 股票代码：600272 | 股票简称：开开实业 | 编号：2023—029 | | --- | --- | --- | | 900943 | 开开 B 股 | | 上海开开实业股份有限公司 股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●上海开开实业股份有限公司（以下简称"公司"）A 股股票于 2023 年 8 月 9 日、2023 年 8 月 10 日、2023 年 8 月 11 日连续 3 个交 易日内日收盘价格涨幅偏离值累计超过 20%，根据《上海证券交易所 交易规则》的相关规定，属于股票交易异常波动的情形。 ●经公司自查并向控股股东上海开开（集团）有限公司（以下简 称"开开集团"）征询，公司控股股东不存在应披露而未披露的信息。 ●经公司控股股东开开集团向公司实际控制人上海静安区国有 资产监督管理委员会（以下简称"静安区国资委"）问询，公司实际控 制人不存在应披露而未披露的信息。 ●公司股价短期波动幅度较大，敬请广大投资者理性投资，注意 投资风险。 （一）生产经营情况 ...

上海开开(集团)有限公司 关于上海开开实业股份有限公司 股票交易异常波动的问询函的回函 三、在你司本次股票异常波动期间,我司不存在买卖你司股票的 行为。 特函告知。 上海开 2023年8月 一、截至本回函之日,我司不存在《上海证券交易所股票上市规 则》所规定的可能对你司股票价格产生较大影响的事项,包括但不限 于重大资产重组、股份发行、收购、债务重组、业务重组、资产剥离、 资产注入、股份回购、股权激励、破产重整、重大业务合作、引进战 略投资者等应披露而未披露的重大事项。 二、经我司向上海市静安区国有资产监督管理委员会问询,也不 存在应披露而未披露的重大事项。 上海开开实业股份有限公司: 《上海开开实业股份有限公司关于股票交易异常波动的问询函》 已收悉,经核查,现复函如下: ...

| | | 上海开开实业股份有限公司 关于参加 2023 年上海辖区上市公司 年报集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开时间：2023 年 5 月 10 日（星期三）下午 15:00-17:00 ●会议召开地点：上证路演中心 （http://roadshow.sseinfo.com） ●会议召开方式：网络文字互动方式 ●投资者可在 2023 年 5 月 6 日 16:00 前 ， 通 过 公 司 邮 箱 dm@chinesekk.com提前留言提问。公司将在业绩说明会上对投资者普 遍关注的问题进行回答。 上海开开实业股份有限公司（以下简称"公司"）已于 2023 年 3 月 30 日在《上海证券报》《香港商报》及上海证券交易所网站 （www.sse.com.cn）披露了公司《2022 年年度报告及摘要》。并将于 2023 年 4 月 28 日在《上海证券报》《香港商报》及上海证券交易所 网站（www.sse.com.cn）披露公司《2023 年第一季度报告》。为进一 步 ...

Financial Performance - In 2022, the company's operating revenue reached RMB 894,171,857.19, an increase of 33.49% compared to RMB 669,830,444.59 in 2021[23] - The net profit attributable to shareholders of the listed company was RMB 39,949,414.62, representing an 83.95% increase from RMB 21,717,156.85 in the previous year[23] - The net profit after deducting non-recurring gains and losses was RMB 14,163,238.65, a significant increase of 229.05% from RMB 4,304,296.82 in 2021[23] - The net cash flow from operating activities was RMB 79,342,921.55, up 197.00% from RMB 26,714,570.66 in the previous year[23] - Total assets at the end of 2022 amounted to RMB 1,207,255,505.50, reflecting a 13.57% increase from RMB 1,062,971,330.52 in 2021[23] - The company achieved operating revenue of 2.24 billion yuan in 2022, an increase of 33.49% compared to 2021[24] - Net profit attributable to shareholders increased by 18.23 million yuan, representing an 83.95% growth year-over-year[24] - Basic earnings per share rose to 0.16 yuan, a 77.78% increase from 0.09 yuan in 2021[24] - The weighted average return on equity improved to 7.26%, up 3.12 percentage points from the previous year[24] - The net cash inflow from operating activities increased by 52.63 million yuan, a 197.00% rise compared to the previous year[26] Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 0.50 per 10 shares to all shareholders, totaling RMB 12,150,000.00[7] - The company does not plan to issue bonus shares or convert capital reserves into share capital for this fiscal year[7] - The proposed cash dividend is RMB 0.50 per 10 shares, amounting to a total distribution of RMB 12,150,000, which is 30.41% of the net profit attributable to shareholders[137] - The company has maintained a consistent cash dividend policy, having distributed dividends for 10 consecutive years, with a payout ratio exceeding 30% of net profit each year[136] Operational Challenges and Strategies - The company faced significant operational pressure in the apparel segment due to market demand shrinkage and intensified competition[25] - The company implemented a dual work management model of "home office + closed office" to ensure operational continuity amid challenges[35] - The company is actively expanding its "big health" transformation strategy, including the establishment of a dental department in its subsidiary[36] - The company is focusing on the "big health" transformation strategy, integrating digitalization into its pharmaceutical and healthcare services[46] - The company is undergoing a strategic transformation towards a "big health" strategy, impacting its operational focus and product offerings[57] Risk Management and Compliance - The company has outlined various risks and countermeasures in its management discussion and analysis section[9] - The company emphasizes the importance of accurate financial reporting and has received a standard unqualified audit report from its accounting firm[6] - The company maintained independence from its controlling shareholder, with no instances of fund or asset occupation reported during the period[99] - The company has established a transparent performance evaluation and incentive mechanism for directors and senior management, with the remuneration linked to actual performance assessments[100] Social Responsibility and Community Engagement - The company provided rent reductions totaling over 3.9 million yuan for 31 small and micro enterprises and individual businesses[42] - The company donated approximately 350,000 yuan worth of traditional Chinese medicine health products to medical workers in Jing'an District[42] - The company has committed a total of 500,000 CNY to poverty alleviation and rural revitalization projects, with all funds allocated to financial support[152] - The company has engaged in a five-year partnership with a village in Yunnan, providing up to 1.5 million CNY in support for rural revitalization efforts[153] Governance and Management Structure - The company held one annual general meeting and two extraordinary general meetings during the reporting period, ensuring compliance with legal requirements for shareholder meetings[98] - The board of directors consists of 9 members, with independent directors actively participating in decision-making processes, ensuring compliance with relevant laws and regulations[99] - The company’s governance structure includes independent directors and a supervisory board, ensuring oversight and compliance[112] - The company has a diverse board with members having extensive experience in various sectors, enhancing its strategic decision-making capabilities[112] Financial Health and Asset Management - The company’s total assets reached ¥1,207,255,505.50 in 2022, up from ¥1,062,971,330.52 in 2021, indicating an increase of approximately 13.6%[200] - Current assets totaled RMB 589,293,001.32, up from RMB 416,604,983.44 in the previous year, indicating a significant increase of about 41.3%[199] - Cash and cash equivalents reached RMB 300,932,076.82, compared to RMB 173,503,223.58 in 2021, representing a growth of approximately 73.4%[199] - Total liabilities increased to ¥629,004,087.41 in 2022, up from ¥516,427,723.90 in 2021, representing a growth of approximately 21.7%[200] Future Outlook and Strategic Initiatives - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion CNY[115] - New product launches are expected to contribute an additional 200 million CNY in revenue, with a focus on expanding the product line in the health sector[115] - The company is investing in new technology development, allocating 100 million CNY for R&D in the upcoming year[115] - The management emphasized the importance of enhancing operational efficiency, targeting a 10% reduction in operational costs over the next year[115]

Financial Performance - The company's operating revenue increased by 201 million RMB, a growth of 59.73% compared to the same period last year[20] - Net profit attributable to shareholders increased by 22.92 million RMB, a growth of 385.49% year-on-year[20] - The basic earnings per share rose to 0.119 RMB, up 395.83% from 0.024 RMB in the same period last year[20] - The weighted average return on net assets increased by 4.21 percentage points to 5.36%[20] - The company's operating revenue for the first half of the year reached ¥536,772,420.36, representing a 59.73% increase compared to ¥336,058,097.29 in the same period last year[22] - Net profit attributable to shareholders was ¥28,860,804.19, a significant increase of 385.49% from ¥5,944,620.17 year-on-year[22] - The net profit after deducting non-recurring gains and losses was ¥21,602,972.24, up 404.94% from ¥4,278,361.27 in the previous year[22] - The company's total assets increased by 12.40% to ¥1,194,815,672.20 from ¥1,062,971,330.52 at the end of the previous year[22] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 101 million RMB, a decline of 392.66% compared to the previous year[21] - The net cash flow from operating activities was negative at -¥74,988,454.75, a decline of 392.66% compared to ¥25,622,940.20 in the same period last year[22] - The company's cash and cash equivalents decreased by 49.75% to CNY 87,180,857.98 from CNY 173,503,223.58 at the end of the previous year[47] - The cash flow from operating activities showed a net outflow of ¥74,988,454.75 in the first half of 2022, contrasting with a net inflow of ¥25,622,940.20 in the same period of 2021[116] - The total cash and cash equivalents at the end of H1 2022 were ¥87,180,857.98, down from ¥234,393,664.60 at the end of the first half of 2021[116] Segment Performance - Revenue from the apparel segment was 19.84 million RMB, a decrease of 3.86 million RMB compared to the same period last year[21] - Revenue from the pharmaceutical segment's daily operations was 194 million RMB, down 115 million RMB year-on-year[21] - The retail sales of the pharmaceutical business increased by 123.21% year-on-year, reaching 267 million yuan, while wholesale sales rose by 49.65% to 230 million yuan[38] - The company faced a 35.82% decline in revenue from its retail and self-owned brand sales due to the pandemic, resulting in a loss of 120.38 million yuan[35] Operational Challenges - The company faced significant operational challenges due to pandemic-related restrictions, impacting retail and service revenues[21] - The company implemented a dual work management model of "remote work + closed office" to maintain operational efficiency during the pandemic[35] - The company successfully held multiple board meetings and shareholder meetings via video conferencing to ensure governance continuity during the pandemic[37] - The company emphasized the importance of pandemic prevention while maintaining production and operational activities, showcasing its commitment to corporate responsibility[36] Strategic Initiatives - The company is focusing on the "big health" transformation in the pharmaceutical sector, leveraging digital empowerment to accelerate new retail initiatives[27] - The company aims to enhance its brand image and expand its product line to cater to younger consumer groups, particularly in the clothing sector[31] - The company is actively developing new products and specifications in response to market demand, particularly in the health and wellness sector[31] - The company is focusing on optimizing its business structure and enhancing consumer experience while expanding its market share in new retail and internet sectors[63] - The company is actively pursuing a "big health" strategic transformation, adjusting its focus based on the performance of its two main business segments, pharmaceuticals and apparel[63] Risk Management - The company emphasizes the importance of risk management in its operations, detailing potential risks and countermeasures in the report[6] - The company faces significant macroeconomic volatility risks due to geopolitical tensions and ongoing pandemic effects, which may impact consumer markets and operational stability[62] - There are risks associated with the transformation and innovation of existing businesses, which may not meet expectations due to market changes and policy directions[63] Corporate Governance and Compliance - The company has no profit distribution plan or capital reserve transfer plan for the half-year period[4] - The company has no significant litigation or arbitration matters during the reporting period[85] - The company has not disclosed any non-operating fund occupation by controlling shareholders or related parties during the reporting period[85] - The company has not received any administrative penalties related to environmental issues during the reporting period[76] - The company has maintained compliance with safety production management responsibilities and improved safety awareness among employees[77] Environmental and Social Responsibility - The company has established an environmental management system certified by the certification group, valid until December 24, 2022[77] - The company has committed to reducing carbon emissions by promoting resource reuse and strict waste management practices[78] - The company has provided a total of up to 1 million yuan in aid for rural revitalization from 2019 to 2022, averaging annual payments[80] - The company is continuing its support for rural revitalization in Yunnan Province with a total aid of up to 1.5 million yuan from 2021 to 2025, also averaging annual payments[80] Shareholder Information - As of the end of the reporting period, the total number of ordinary shareholders was 47,893[92] - The largest shareholder, Shanghai Kai Kai (Group) Co., Ltd., holds 64,409,783 shares, accounting for 26.51% of the total shares[95] - Shanghai Jin Xing Trading Company holds 3,000,000 shares, which are currently frozen due to a pledge[98] Accounting and Financial Reporting - The financial statements are prepared based on the going concern assumption, with no significant factors affecting the company's ability to continue operations within the next 12 months[130] - The company adheres to the accounting policies as per the Chinese Accounting Standards, ensuring a true and complete reflection of its financial status[131] - The company’s accounting period runs from January 1 to December 31 each year, with a business cycle of 12 months[132][133] - The company has not reported any changes in accounting policies or significant errors in prior periods that would affect the current financial statements[129] Financial Assets and Liabilities - Financial assets are classified based on the business model for managing them and their cash flow characteristics, with initial measurement at fair value[144] - Debt instruments are measured at amortized cost if the business model aims to collect contractual cash flows, which consist solely of principal and interest payments[144] - The company recognizes expected credit losses based on historical data, current conditions, and future economic forecasts, with a focus on the probability-weighted present value of cash flow differences[147] - Financial liabilities are primarily measured at amortized cost, including notes payable, accounts payable, and borrowings[156] Inventory and Asset Management - Inventory is measured at the lower of cost and net realizable value, with provisions for inventory write-downs recognized when costs exceed net realizable values[163] - The company adopts a perpetual inventory system for inventory management[164] - Long-term equity investments are accounted for using the cost method or equity method depending on the level of control or significant influence[166] Employee Benefits and Provisions - Employee benefits include various forms of compensation for services rendered, including short-term and post-employment benefits[183] - Short-term employee benefits are recognized as liabilities and included in the current period's profit or loss[184] - The company recognizes termination benefits when it cannot withdraw the offer of such benefits or when it confirms related restructuring costs[187]

Financial Performance - The company's operating revenue for 2021 was RMB 669,830,444.59, a decrease of 12.08% compared to RMB 761,821,632.96 in 2020[20] - The net profit attributable to shareholders for 2021 was RMB 21,717,156.85, representing an increase of 58.81% from RMB 13,674,803.24 in 2020[20] - The net cash flow from operating activities decreased by 67.29% to RMB 26,714,570.66 in 2021, down from RMB 81,659,668.42 in 2020[20] - The total assets at the end of 2021 were RMB 1,062,971,330.52, an increase of 1.87% from RMB 1,043,469,065.22 at the end of 2020[20] - The basic earnings per share for 2021 was RMB 0.09, a 50% increase from RMB 0.06 in 2020[21] - The weighted average return on equity for 2021 was 4.14%, an increase of 1.50 percentage points from 2.64% in 2020[21] - The net profit after deducting non-recurring gains and losses for 2021 was RMB 4,304,296.82, an increase of 89.54% from RMB 2,270,939.53 in 2020[20] - The company's net assets attributable to shareholders at the end of 2021 were RMB 535,431,490.48, a 3.70% increase from RMB 516,308,227.42 at the end of 2020[20] Business Strategy and Transformation - The company plans to explore three core business areas: pharmaceutical health, medical health, and elderly care health, as part of its "big health" strategic transformation[20] - The company is focusing on the "big health" transformation strategy, aiming for sustainable high-quality development[31] - The company is actively pursuing a "big health" transformation strategy, aiming to expand into new health-related business areas and enhance revenue and profit growth points[41] - The company is exploring the possibility of opening self-operated medical institutions to expand its healthcare business layout[41] - The company aims to enhance its management quality and operational performance while navigating complex market challenges[93] - The company is focusing on expanding its healthcare segment while consolidating existing businesses, aiming for a "three verticals and three horizontals" strategy in digital health, pharmaceuticals, and medical care[95] Market Trends and Challenges - The pharmaceutical segment's revenue has been declining annually due to the impact of national drug procurement policies and the cancellation of long-term prescriptions for chronic diseases[22] - In 2021, the company's net profit was largely derived from non-operating gains, including government subsidies and costs related to comprehensive reforms, indicating a lack of sustainability[22] - The retail sector is experiencing a shift towards online channels, driven by the COVID-19 pandemic, which is reshaping consumer behavior and business models[33] - The healthcare market is expanding due to diverse consumer health needs and supportive government policies, creating opportunities for growth in the pharmaceutical retail sector[33] - The company is facing macroeconomic risks and industry competition, particularly from the impact of the pandemic and evolving consumer behaviors in the retail sector[98] Operational Efficiency and Reforms - The company is implementing comprehensive reforms in its apparel segment to improve operational efficiency amid challenges from international trade and the pandemic[22] - The clothing sector is undergoing comprehensive reform, focusing on new retail models and enhancing e-commerce marketing efforts to seek new growth opportunities[36] - The company is committed to enhancing its governance and risk management practices to ensure compliance and operational efficiency[94] - The company has established a robust internal control framework that meets regulatory requirements and supports its management and development needs[137] Legal and Compliance Issues - The company is involved in a significant litigation case with China Everbright Bank regarding a bill dispute, which has been ongoing since January 2005[157] - The Shenzhen Intermediate People's Court ruled against the company's claims in March 2010, leading the company to file an appeal to the Guangdong High People's Court[157] - The company is currently navigating multiple legal challenges that may impact its financial stability and operational strategy[160] - The ongoing litigation and asset freezes could affect the company's market expansion and investment strategies in the near future[160] Shareholder and Governance Matters - The company plans to distribute a cash dividend of RMB 0.27 per 10 shares, totaling RMB 6,561,000, which represents 30.21% of the net profit attributable to shareholders for 2021[134] - The company has maintained a consistent cash dividend policy, distributing dividends for nine consecutive years, with a payout ratio exceeding 30% of net profit each year[133] - The company continues to enhance its corporate governance structure and internal control mechanisms to promote sustainable and healthy development[104] - The company emphasizes the importance of adhering to the regulations set forth in the Company Law and corporate governance guidelines[117] Future Outlook and Growth Plans - The company provided guidance for the next quarter, expecting revenue to be between $1.3 billion and $1.4 billion, indicating a growth rate of 10% to 15%[110] - Market expansion plans include entering three new international markets by the end of the year, projected to increase user base by 25%[110] - The company plans to enhance its product structure and diversify operations to adapt to policy changes and consumer demand, leveraging digital and intelligent methods to develop new retail markets[95] - The company is considering strategic acquisitions to bolster its market position, with a budget of $100 million allocated for potential deals[110] Employee and Workforce Development - The company has recognized the impact of new leasing standards, resulting in the recognition of right-of-use assets amounting to approximately ¥29.78 million and lease liabilities of approximately ¥20.27 million[149] - The company has focused on enhancing employee training to improve work efficiency and support performance growth[131] - The company reported a total of 489 employees, with 414 in sales and 23 in finance[129] Environmental and Social Responsibility - The company has adhered to environmental protection standards, ensuring that medical wastewater is treated according to national regulations[140] - The company promotes sustainable development by reducing energy consumption and encouraging eco-friendly practices among employees[141] - The company has provided emergency supplies during local pandemic outbreaks, receiving high recognition from government departments and customers[144] - The company continues to assist rural revitalization efforts by partnering with local communities to improve living conditions and support local residents[145]

Financial Performance - Operating revenue declined by 10.25% to CNY 643,029,865.29 for the first nine months compared to the same period last year[7]. - Net profit attributable to shareholders increased by 33.12% to CNY 26,741,669.78 year-on-year[7]. - Basic earnings per share rose by 37.50% to CNY 0.11 compared to CNY 0.08 in the same period last year[7]. - Total operating revenue for Q3 2018 was ¥198.72 million, a decrease of 19.5% compared to ¥247.03 million in Q3 2017[27]. - Net profit for Q3 2018 reached ¥5.41 million, an increase of 51.1% from ¥3.58 million in Q3 2017[27]. - The company reported a total profit of ¥7.92 million for Q3 2018, up from ¥7.32 million in Q3 2017[27]. Cash Flow - Net cash flow from operating activities turned negative at CNY -20,692,751.19, a decrease of 761.99% compared to the previous year[7]. - Operating cash flow for the period from January to September was negative at -20,692,751.19 RMB, compared to a positive cash flow of 3,125,837.37 RMB in the same period last year[32]. - Cash inflow from operating activities decreased to 620,825,329.24 RMB, down 12.0% from 705,525,203.01 RMB year-on-year[32]. - Cash outflow from operating activities increased to 641,518,080.43 RMB, compared to 702,399,365.64 RMB in the previous year, resulting in a net cash outflow[32]. - The ending balance of cash and cash equivalents was 81,696,246.95 RMB, down from 122,188,588.71 RMB year-on-year[32]. - The company reported a significant decrease in cash flow from sales of goods and services, totaling 609,177,926.04 RMB, down 12.7% from 698,104,385.07 RMB in the previous year[32]. Assets and Liabilities - Total assets decreased by 5.86% to CNY 980,827,824.65 compared to the end of the previous year[7]. - Cash and cash equivalents decreased by 49.89% to CNY 81,696,246.95 compared to the beginning of the year[13]. - Total liabilities decreased to CNY 481,957,929.57 from CNY 539,690,041.34, reflecting a reduction in financial obligations[21]. - Total current assets increased to CNY 196,724,842.70 from CNY 177,713,796.78, representing an increase of approximately 9%[23]. - Total non-current assets decreased to CNY 431,527,153.80 from CNY 459,010,009.53, reflecting a decline of about 6%[23]. - Total equity increased slightly to CNY 456,606,826.20 from CNY 455,181,044.84, showing a marginal growth of about 0.3%[24]. Shareholder Information - The number of shareholders reached 31,013 at the end of the reporting period[10]. - The largest shareholder, Shanghai Kaikai (Group) Co., Ltd., holds 26.51% of the shares[10]. Other Financial Metrics - The weighted average return on equity increased by 1.26 percentage points to 5.33%[7]. - The company’s investment income showed a significant decline, reporting a loss of CNY -1,246,623.27 compared to a profit of CNY 2,998,488.81 in the previous period, a change of -141.58%[18]. - Other comprehensive income decreased to CNY 38,864,820.09 from CNY 58,555,166.64, a reduction of approximately 34%[24]. - The company experienced a significant increase in asset impairment losses, reporting ¥10.21 million in Q3 2018 compared to a loss of ¥5.31 million in Q3 2017[27].

Financial Performance - The company's operating revenue for the first half of 2018 was ¥444,305,232.18, a decrease of 5.35% compared to ¥469,415,258.67 in the same period last year[22]. - Net profit attributable to shareholders increased by 31.05% to ¥21,381,578.03 from ¥16,315,425.48 year-on-year[22]. - The net profit after deducting non-recurring gains and losses surged by 98.01% to ¥14,396,767.23 compared to ¥7,270,637.47 in the previous year[22]. - The total profit for the period was 31.65 million yuan, an increase of 33.23% compared to the same period last year[34]. - The net profit reached 21.37 million yuan, up 33.88% year-on-year, while the net profit attributable to shareholders was 21.38 million yuan, an increase of 31.05% from 16.32 million yuan[34]. - The company reported a revenue of 3.83 billion RMB and a net profit of over 17 million RMB for the first half of 2018[57]. - The company’s subsidiary, Shanghai Lei Yun Shang Pharmaceutical West District Co., Ltd. achieved a revenue of 3.52 billion RMB and a net profit of 17.11 million RMB during the same period[57]. - The company reported a total comprehensive income loss of RMB 24,611,735.67 for the current period[113]. Cash Flow and Liquidity - The net cash flow from operating activities rose by 31.93% to ¥36,329,061.27 from ¥27,537,526.26 year-on-year[22]. - Cash and cash equivalents increased by 7.24% to ¥174,849,326.33, enhancing liquidity[46]. - The ending cash and cash equivalents balance increased to ¥174,849,326.33, compared to ¥129,626,798.96 at the end of the previous period, representing a growth of approximately 35.0%[104]. - The cash inflow from sales of goods and services was ¥446,108,648.74, down from ¥464,618,948.74, indicating a decrease of about 4.0%[104]. - The company has no cash and cash equivalents restricted for use, indicating full liquidity for operational needs[178]. Asset Management - The total assets at the end of the reporting period were ¥1,029,259,905.61, a decrease of 1.21% from ¥1,041,907,254.63 at the end of the previous year[22]. - The inventory decreased by 22.01% to ¥112,439,906.12, suggesting effective inventory management[46]. - Total current assets decreased from ¥525,949,218.32 to ¥508,766,857.32, a decline of approximately 3.4%[93]. - The total inventory at the end of the period was ¥115,694,169.81, with a provision for inventory depreciation of ¥3,254,263.69[199]. Investment and Growth Strategies - The company plans to increase its investment in the pharmaceutical sector by expanding its stake in Shanghai Jing'an Pharmaceutical Co., Ltd., which is expected to positively impact the pharmaceutical segment in the long term[38]. - The company launched 10 new products in the ginseng series, 18 new sachets, 4 new health teas, and 1 new food-grade medicinal supplement during the reporting period[36]. - The company plans to focus on market expansion and new product development in the upcoming quarters to drive growth[100]. Marketing and Sales - The company has actively expanded its marketing channels and developed a multi-channel marketing model to adapt to the new retail landscape[36]. - The company launched several marketing campaigns, including "Eternal Classics" and "Mother's Day Summer Silk Women's Wear," to boost sales[40]. - Online retail sales in China reached 408.10 billion yuan in the first half of 2018, growing by 30.1% year-on-year, with physical goods online retail sales accounting for 17.4% of total retail sales, an increase of 3.6 percentage points[30]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,061[78]. - The largest shareholder, Shanghai Kaikai (Group) Co., Ltd., holds 64,409,783 shares, representing 26.51% of total shares[81]. - The company has not proposed any profit distribution or capital reserve transfer plans for the reporting period[65]. Risk Factors - The company faces significant risks including macroeconomic fluctuations, market competition, and the impact of e-commerce on consumer behavior[60]. - The company is currently in the process of cultivating new economic growth points, but these investments are still in the input and cultivation stage and may not contribute to performance in the short term[61]. Compliance and Governance - The company continues to engage Lixin Certified Public Accountants for auditing services, ensuring compliance and oversight[67]. - There were no significant changes in accounting policies, estimates, or methods compared to the previous accounting period[75]. - The company has not disclosed any environmental information as it is not classified as a key pollutant discharge unit[74]. Financial Instruments and Accounting Policies - Financial instruments include financial assets, financial liabilities, and equity instruments, classified at initial recognition based on their nature and measurement[133]. - The company recognizes investment income from financial assets based on fair value changes and calculates interest income for held-to-maturity investments using amortized cost and effective interest rates[134]. - The company assesses the impairment of financial assets at the balance sheet date and recognizes impairment losses if there is objective evidence of impairment[138].